What are the indications for use of chimeric antigen receptor (CAR) T-cell therapy?

Updated: Dec 17, 2020
  • Author: Sameh Gaballa, MD, MS; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


Currently, CAR T cells are approved by the US Food and Drug Administration (FDA) for the following indications:

  • Acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse, in patients younger than 25 years of age
  • Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after failure of at least 2 prior lines of therapy
  • R/R mantle cell lymphoma, after failure of therapy with a Bruton's tyrosine kinase (BTK) inhibitor

The first report of CAR T-cell therapy was in 2010, in a patient with advanced follicular lymphoma. Kochenderfer et al described dramatic regression of the lymphoma after infusion of CAR T cells engineered to target CD19. [6] Since then, several trials have been launched; key studies will be reviewed in this article.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!